The potential impact that siRNA technology can have on the multi- billion dollar skin care market cannot be overstated. The epidermis is the body’s largest organ and, by some assessments, the most accessible when using topical delivery agents. Overall, the field of gene therapy has been plagued by inefficient delivery of potent gene-silencers and off-target effects, drastically limiting the development of therapeutic siRNAs. Despite these setbacks, this situation represents a unique opportunity for the cosmetic scientist to develop revolutionary products that are capable of preventing or treating debilitating skin disorders.